Answers are grounded in this paper and cite their sources.
A pooled analysis assesses evolocumab's efficacy in lowering cholesterol in Japanese patients, indicating significant cardiovascular benefits.
Aims: Lowering low-density lipoprotein cholesterol (LDL-C) is essential for reducing the risk of atherosclerotic cardiovascular disease (ASCVD). This study assessed the clinical efficacy of evolocumab, a human monoclonal antibody targeting PCSK9, in Japanese patients using data from the PROFICIO program.
No takes yet. Share an insight, caveat, or question.
Oyama et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: